Avant Immunotherapeutics führt Kooperatinsgespräche und steigt im Hoch um 39 % !!!! - 500 Beiträge pro Seite

[360 Modena]

Hi Leute,

schaut euch mal 874446 an ( Avant Immmunotherapeutics ). Da könnte in den nächsten Wochen einiges zu holen sein. Der Chart sieht derzeit auch glänzend aus. Ich bin seit ein paar tagen wieder eingestiegen.

Man verhandelt mit Pfizer, Merck und noch einem Pharmariesen.

[360 Modena]

Nachbörslich über 6$ !!!

Ist das der "break out" in Richtung 10$ ?

[Braini]

nachbörslich 5.95... also nich übertreiben. ich würde mal den montag abwarten . die letztze (verlängerte ) stunde war nicht reell, da gabs viel merkwürdige kurssprünge..

[360 Modena]

Es geht weiter in Richtung 8$. Heute wieder mit über 11% im Plus. Die Shorties steigen aus!!!!

[Blind Guardian]

Hi,

Avant ist in den letzten Monaten ziemlich mit nach unten gezogen worden. Das hat nicht unbedingt etwas mit der Firma zu tun...der Markt war eben nicht bereit, solange noch keine Produkte auf dem Markt sind, das vorhandene Potential zu honorieren.
Dabei haben auch viele Shorties versucht den Wert dauerhaft unten zu halten.

Bei positiven Nachrichten kommt es dann natürlich zu derartigen Kurssprüngen...(Short-Squeeze)

Man sollte das aber nicht unbedingt überbewerten....wenn nichts nachkommt, dann wird der Kurs sehr schnell wieder zurückfallen.... (so um die 5$)

Wer über einen sehr kurzen Anlagehorizont verfügt, sollte Gewinne mitnehmen, wer langfristig orientiert ist, der sollte bereit sein, mindestens 1-2 Jahre durchzuhalten....

Beide Strategien könnten sich durchaus lohnen......

MFG

B.G.

[erkilein]

und heute fällt es im tief um 30 %

TP 10 für babies auf Eis gelegt

AVANT Immunotherapeutics Reports Second Quarter 2001 Financial Results

TP10 Pediatric Phase IIb Studies Placed on Clinical Hold

NEEDHAM, Mass., Aug 1, 2001 /PRNewswire via COMTEX/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN chart, msgs) today reported financial results for the second quarter ended June 30, 2001. The Company reported a net loss of $5.7 million, or $.10 per share, for the second quarter of 2001 compared to a net loss of $2.7 million, or $.05 per share, for the second quarter of 2000. The results for the second quarter of 2001 primarily reflect a substantial increase in research and development expense compared to the same period in 2000. This increase resulted from increased clinical trials costs and clinical materials costs incurred in connection with the Company`s TP10 and CETi-1 clinical programs, as well as the addition of the operating costs of Megan Health, which AVANT acquired in December 2000. The Company ended the quarter with cash and cash equivalents of $40.7 million.

For the six months ended June 30, 2001, the Company reported a net loss of $9.7 million, or $.17 per share, compared to a net loss of $4.8 million, or $.10 per share, for the six months ended June 30, 2000. The six-month results for 2001 reflect an increase in net loss of $4.9 million compared to the same period in 2000. This increase in net loss primarily reflects a substantial increase in operating expense offset by an increase in revenue. The increase in revenue reflects differences in revenue recognized from the amortization of nonrefundable license fees received from our collaborators between the comparable six-month periods, revenue from SBIR grants recorded in 2001, and the addition of Megan Health revenue in 2001. The increase in operating expense is primarily due to increased clinical trials costs and clinical materials costs incurred in connection with the Company`s clinical programs. It also results from the addition of the operating costs of Megan Health in the six-month period in 2001 and an increase in the charges for amortization of acquired intangible assets related to the Megan Health acquisition in late 2000.

TP10 Pediatric Phase IIb Studies Placed on Clinical Hold

The Company suspended enrollment in its two Phase IIb studies of TP10 in infants undergoing cardiac surgery following receipt from the Data Safety Monitoring Board (DSMB) of a request for additional detailed information from these studies, including patient records for reported serious adverse events. The DSMB has met and reviewed the information requested, and has indicated that patient enrollment may be reinstated, with the recommendation to add additional laboratory tests to the study protocol. The U.S. Food and Drug Administration (FDA) has been notified that patient enrollment in the studies has temporarily been suspended. In response, the FDA has placed the pediatric programs on clinical hold, pending their review of these additional data. While the Company has not received written notification of the FDA`s specific questions and requests, it is working closely with the Agency to resolve this matter expeditiously. AVANT believes that this is a short-term situation and the Company is committed to complying with the FDA`s formal requests as soon as they are received. The Agency`s review of the pediatric TP10 studies does not affect the adult cardiac surgery program, which is continuing as planned.

"The infants in these studies are critically ill and are undergoing major reconstructive cardiac surgery that requires long times on cardiopulmonary bypass circuits which can result in considerable mortality and morbidity in this patient group," said Dr. Alistair Wheeler MD, Vice President, Medical Affairs of AVANT. "We have taken appropriate action to suspend enrollment in these trials pending review by the FDA of all data. We believe the serious adverse events reported by the investigators are consistent with those seen in this population of infants. We are very encouraged by the DSMB`s conclusion, after reviewing detailed data we provided them, that enrollment in the studies could be reinstated. We look forward to reviewing the data with the FDA."

Other Clinical Development Programs

AVANT remains focused on developing products that use novel applications of immunology to harness the human immune response to prevent and treat disease. The Company continues to make progress this year in advancing multiple products in its pipeline to later stages of clinical development.

During the quarter, AVANT announced results from the Phase IIb human challenge study of its single dose, oral cholera vaccine, Peru-15. Peru-15 showed 100% protection against moderate and severe diarrhea and 93% protection against any diarrhea. The study results suggest that, if confirmed by further investigation, Peru-15 may be an excellent candidate as a potential single dose, oral vaccine for travelers going to areas where cholera is endemic. AVANT also announced a manufacturing agreement with Bio Sidus S.A. of Buenos Aires, Argentina for the production of commercial quantities of Peru-15. AVANT will move rapidly to complete the manufacture of cGMP grade material this year and to initiate pivotal trials in the first half of 2002. Development of a safe, effective cholera vaccine is the first step in establishing AVANT`s travelers` vaccine franchise.

In addition to the two placebo-controlled Phase IIb studies of TP10 in babies (one in babies born with hypoplastic left heart syndrome, who often have high morbidity and mortality after heart surgery, and the second also in the pediatric cardiac surgery setting, but with a lower risk infant population), AVANT is actively enrolling a placebo-controlled Phase II trial of TP10 in approximately 600 adult patients undergoing cardiac surgery utilizing cardiopulmonary bypass. The objective of these three studies is to assess the ability of TP10 to mitigate the injury to the heart, brain and other organs that occurs when patients are placed on cardiopulmonary bypass circuits, thus potentially improving post-operative outcomes.

In February 2001, AVANT announced preliminary results from a double- blinded placebo-controlled extension of its earlier completed Phase I trial of its CETP vaccine (CETi-1) in healthy adult volunteers receiving a second dose of the vaccine. CETi-1 is being developed for the management of patients with low levels of HDL (high-density lipoprotein) cholesterol. Results from the extension study showed measurable antibody titers in all dose groups treated with the investigational vaccine and suggest a dose-response relationship. These data have been extremely helpful in designing a Phase II study, which AVANT plans to begin later this summer.

During the next twelve months, AVANT expects its partner, GlaxoSmithKline, to initiate Phase III studies of its investigational rotavirus vaccine, Rotarix(TM). This product is a two-dose oral rotavirus vaccine that has been shown to be helpful in preventing rotavirus gastroenteritis (RGE) disease in young children for at least two years following the vaccine`s administration. The design, timing and execution of the clinical program for Rotarix(TM) is the responsibility of GlaxoSmithKline.